Reversal of p53-induced cell-cycle arrest

Molecular Carcinogenesis

Volumn 24, Issue 1, 1999, Pages 7-14

  Bates, Stewart ^a   Hickman, Emma S ^a,b   Vousden, Karen H ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN A; CYCLIN DEPENDENT KINASE; DACTINOMYCIN; DNA; PROTEIN P21; PROTEIN P53; RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTOR E2F;

APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CELL CYCLE; CELL CYCLE G2 PHASE; CONTROLLED STUDY; DNA SYNTHESIS; FLOW CYTOMETRY; GAMMA IRRADIATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; WESTERN BLOTTING;

APOPTOSIS; CELL CYCLE; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; DACTINOMYCIN; DNA REPLICATION; DNA, NEOPLASM; ENZYME INHIBITORS; G1 PHASE; G2 PHASE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, P53; HUMANS; KINETICS; MUTAGENESIS; TIME FACTORS; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0032953375     PISSN: 08991987     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2744(199901)24:1<7::AID-MC2>3.0.CO;2-5     Document Type: Article

References (34)

1. Donehower LA. The p53-deficient mouse: A model for basic and applied cancer studies. Semin Cancer Biol 1996;7:269-278.
2. Greenblatt MS, Bennett WP, Hollstein M, Harris CC. Mutations in the p53 humor suppressor gene: Clues to cancer etiology and molecular pathogenesis. Cancer Res 1994;54:4855-4878.
3. Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 1990;63:1129-1136.
4. Crook T, Wrede D, Tidy JA, Mason WP, Evans DJ, Vousden KH. Clonal p53 mutation in primary cervical cancer: Association with human-papillomavirus-negative tumours. Lancet 1992;339: 1070-1073.
5. Oliner JD, Kinzler KW, Meltzer PS, George DL, Vogelstein B. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 1992;358:80-83.
6. Hartwell L. Defects in a cell cycle checkpoint may be responsible for the genomic instability of cancer cells. Cell 1992;71:543-546.
7. Rowan S, Ludwig RL, Haupt Y, et al. Specific loss of apoptotic but not cell cycle arrest function in a human tumour derived p53 mutant. EMBO J 1996;15:827-838.
8. Brugarolas J, Chandrasekaran C, Gordon JI, Beach D, Jacks T, Hannon GJ. Radiation-induced cell cycle arrest compromised by p21 deficiency. Nature 1995;377:552-556.
9. CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell 1995;82:675-684.
10. Waldman T, Kinzler KW, Vogelstein B. p21 is necessary for the p53-mediated G1 arrest in human cancer cells. Cancer Res 1995;55:5187-5190.
11. Cip1/Waf1 at both the G1/S and the G2/M cell cycle transitions: pRb is a critical determinant in blocking DNA replication and in preventing endoreduplication. Mol Cell Biol 1998;18:629-643.
12. Waf1/Cip1 expression. Oncogene, 1998;17:1691-1703.
13. Polyak K, Waldman T, He T-C, Kinzler KW, Vogelstein B, Genetic determinants of p53-induced apoptosis and growth arrest. Genes Dev 1996;10:1945-1952.
14. Hermeking H, Lengauer C, Polyak K, et al. 14-3-3σ is a p53-regulated inhibitor of G2/M progression. Mol Cells 1997; 1:3-11.
15. Smith ML, Chen I-T, Zhan Q, et al. Interaction of the p53-regulated protein Gadd45 with proliferating cell nuclear antigen. Science 1995;266:1376-1380.
16. Harris CC. Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies. J Natl Cancer Inst 1996;88:1442-1455.
17. Bates S, Vousden KH. p53 in signalling checkpoint arrest or apoptosis. Curr Opin Genet Dev 1996;6:1-7.
18. Hall M, Peter G. Genetic alterations of cyclins, cyclin dependent kinases and cdk inhibitors in human cancers. Adv Cancer Res 1996;68:67-108.
19. Phillips AC, Bates S, Ryan KM, Helm K, Vousden KH. Induction of DNA synthesis and apoptosis are separable functions of E2F-1. Genes Dev 1997;11:1853-1863.
20. Hsieh J-K, Fredersdorf S, Kouzarides T, Martin K, Lu X. E2F-1 induced apoptosis requires DNA binding but not transactivation and is inhibited by the retinoblastoma protein through direct interaction. Genes Dev 1997;11:1840-1852.
21. Field SJ, Tsai F-Y, Kuo F, et al. E2F-1 functions in mice to promote apoptosis and suppress proliferation. Cell 1996;85:549-561.
22. Yamasaki L, Jacks T, Bronson R, Goillot E, Harlow E, Dyson N. Tumor induction and tissue atrophy in mice lacking E2F-1. Cell 1996;85:537-548.
23. ARF links the tumour suppressor RB and p53. Nature 1998;395:124-125.
24. Morgenbesser SD, Williams BO, Jacks T, DePinho RA. p53-dependent apoptosis produced by Rb-deficiency in the developing mouse lens. Nature 1994;371:72-74.
25. Wu XW, Levine AJ. p53 and E2F-1 cooperate to mediate apoptosis. Proc Natl Acad Sci USA 1994;91:3602-3606.
26. Di Leonardo A, Linke SP, Clarkin K, Wahl GM. DNA damage triggers a prolonged p53-dependent G1 arrest and long-term induction of Cip1 in normal human fibroblasts. Genes Dev 1994;8:2540-2551.
27. Linke SP, Clarkin KC, Di Leonardo A, Tsou A, Wahl GM. A reversible, p53-dependent G0/G1 cell cycle arrest induced by ribonucleotide depletion in the absence of detectable DNA damage. Genes Dev 1996;10:934-947.
28. Gadbois DM, Bradbury EM, Lehnert BE. Control of radiation-induced G1 arrest by cell-substratum interactions. Cancer Res 1997;57:1151-1156.
29. Hickman ES, Bates S, Vousden KH. Perturbation of the p53 response by human papillomavirus type 16E7. J Virol 1997;71: 3710-3718.
30. Friedlander P, Haupt Y, Prives C, Oren M. A mutant p53 that discriminated between p53 responsive genes cannot induce apoptosis. Mol Cell Biol 1996;16:4961-4971.
31. Banks L, Matlashewski G, Crawford L. Isolation of human p53 specific monoclonal antibodies and their use in studies of human p53 expression. Eur J Biochem 1986;159:529-534.
32. Vojtesek B, Bartek J, Midgley CA, Lane DP. An immunochemical analysis of the human nuclear phosphoprotein p53. J Immunol Methods 1992;151:237-244.
33. Kessis TD, Slebos RJ, Nelson WG, et al. Human papillomavirus 16 E6 expresson disrupts the p53-mediated cellular response to DNA damage. Proc Natl Acad Sci USA 1993;90:3988-3992.
34. Wuarin J, Nurse P. Regulating S phase: CDKs, licensing and proteolysis. Cell 1996;85:785-787.